(Source: American College of Cardiology Foundation) For close to 100 years since the introduction of insulin for clinical use in 1922, no medication designed to treat hyperglycemia associated with diabetes mellitus has demonstrated benefit for cardiovascular risk in randomized cardiovascular clinical outcomes trials. Yet, since late 2015, when the results of the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) Trial were reported, three such medications (empagliflozin, a sodium glucose cotransporter 2 [SGLT2] inhibitor; and liraglutide and semaglutide, both glucagon-like peptide [GLP] 1 receptor agonists) have been shown to...
↧